May 29, 2019

Akero Therapeutics Initiates Phase 2a Clinical Trial of Investigational Therapy AKR-001 for the Treatment of NASH

Akero Therapeutics announced today that it has screened the first patient for its Phase 2a clinical trial evaluating AKR-001, the company’s lead product candidate for the treatment of NASH.

Read More

May 1, 2019

Akero Therapeutics Appoints Bill White as CFO and Head of Corporate Development

Mr. White joins Akero from Deutsche Bank, where he was a Managing Director and Head of U.S. Life Sciences Investment Banking…

Read More

April 23, 2019

Akero Therapeutics Appoints Industry Veteran Jane Pritchett Henderson to Board of Directors

Ms. Henderson brings over 30 years of biotech industry experience in capital raising, business development and operations…

Read More

January 4, 2019

Akero Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

Akero Therapeutics announces that the company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Read More

December 12, 2018

Akero Therapeutics Announces $70 Million in New Financing

Akero Therapeutics announces the company has closed $70 million in new financing, which will support the advancement of Akero’s lead clinical candidate AKR-001.

Read More

December 6, 2018

Akero Therapeutics Appoints Mark Iwicki to its Board of Directors

Akero Therapeutics today announced the appointment of Mark Iwicki, chairman and CEO of Kala Pharmaceuticals, to Akero’s Board of Directors…

Read More

October 17, 2018

Akero Therapeutics Expands Leadership Team

Kitty Yale joins Akero from Gilead Sciences, Inc. where she led global clinical operations and management of the company’s oncology, HIV, inflammation and liver disease trials. She will direct Akero’s …

Read More

September 11, 2018

Andrew Cheng, MD, PhD Joins Akero Therapeutics as President and Chief Executive Officer

Andrew Cheng, MD, PhD, as President and Chief Executive Officer. Dr. Cheng joins Akero Therapeutics after nearly two decades at Gilead Sciences, Inc. …

Read More

June 25, 2018

Akero Therapeutics Closes $65 Million Series A Financing to Advance New Treatments for Serious Metabolic Diseases

Today announced the completion of a $65 million Series A financing. The financing will be used to advance Akero’s lead clinical program AKR-001…

Read More


West coast headquarters

170 Harbor Way
3rd Floor
South San Francisco, CA 94080

East coast office

400 Technology Square
10th Floor
Cambridge, MA 02139

© 2019 Akero Therapeutics, Inc. All rights reserved. Terms of Use.